share_log

Johnson & Johnson | 424B5: Prospectus

Johnson & Johnson | 424B5: Prospectus

强生 | 424B5：募资说明书
美股SEC公告 ·  05/13 08:39
Moomoo AI 已提取核心信息
Johnson & Johnson, a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of senior unsecured notes. The notes, offered in various denominations and maturities, will pay interest semiannually and are expected to rank equally with the company's other unsecured and unsubordinated debt. The prospectus supplement, dated May 13, 2024, is part of an effective registration statement filed with the SEC and is not an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. The notes will be issued in minimum denominations of $2,000 with additional increments of $1,000. Johnson & Johnson may redeem the notes at any time...Show More
Johnson & Johnson, a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of senior unsecured notes. The notes, offered in various denominations and maturities, will pay interest semiannually and are expected to rank equally with the company's other unsecured and unsubordinated debt. The prospectus supplement, dated May 13, 2024, is part of an effective registration statement filed with the SEC and is not an offer to sell the securities in any jurisdiction where the offer or sale is not permitted. The notes will be issued in minimum denominations of $2,000 with additional increments of $1,000. Johnson & Johnson may redeem the notes at any time, subject to certain conditions. The underwriters for the offering are J.P. Morgan, BofA Securities, and Citigroup. The proceeds from the offering are intended for general corporate purposes, including the recently announced acquisition of Shockwave Medical, Inc., subject to shareholder and regulatory approvals. The offering is expected to close on or about a date to be announced in 2024.
领先的医疗保健公司强生公司宣布根据第424（b）（5）条向美国证券交易委员会（SEC）提交了一份发行一系列优先无担保票据的初步招股说明书补充文件。这些票据以不同的面额和期限发行，将每半年支付一次利息，预计将与公司的其他无抵押和无次级债务持平。2024年5月13日的招股说明书补充文件是向美国证券交易委员会提交的有效注册声明的一部分，不是在任何不允许要约或出售的司法管辖区出售证券的提议。这些票据将以最低面额为2,000美元发行，另外增量为1,000美元。强生可以随时兑换票据，但须遵守某些条件。此次发行的承销商是摩根大通、美银证券和花旗集团。此次发行的收益将用于一般公司用途，包括最近宣布的对Shockwave Medical, Inc. 的收购，但须获得股东和监管部门的批准。此次发行预计将于2024年结束，或大约在2024年宣布。
领先的医疗保健公司强生公司宣布根据第424（b）（5）条向美国证券交易委员会（SEC）提交了一份发行一系列优先无担保票据的初步招股说明书补充文件。这些票据以不同的面额和期限发行，将每半年支付一次利息，预计将与公司的其他无抵押和无次级债务持平。2024年5月13日的招股说明书补充文件是向美国证券交易委员会提交的有效注册声明的一部分，不是在任何不允许要约或出售的司法管辖区出售证券的提议。这些票据将以最低面额为2,000美元发行，另外增量为1,000美元。强生可以随时兑换票据，但须遵守某些条件。此次发行的承销商是摩根大通、美银证券和花旗集团。此次发行的收益将用于一般公司用途，包括最近宣布的对Shockwave Medical, Inc. 的收购，但须获得股东和监管部门的批准。此次发行预计将于2024年结束，或大约在2024年宣布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息